Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.72 ▼ -0.04
(-2.27%)
MKT CAP: $108.4M • VOL: 878.8K
52W L $2 52W H $5
VYGR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $40.4M | $80.0M | $250.0M |
| YoY Revenue Growth % | -49.5% | -68.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$131.8M | -$83.3M | $122.0M |
| Operating Margin % | -80.0% | -80.0% | 48.8% |
| Net Income (GAAP) | -$119.7M | -$65.0M | $132.3M |
| EBITDA (Normalized) | -$129.8M | -$80.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$132.5M | -$15.3M | $77.9M |
| Capital Expenditures (CapEx) | $2.6M | $3.5M | — |
| Free Cash Flow (FCF) | -$135.1M | -$18.8M | $77.9M |
| FCF Margin % | -80.0% | -23.5% | 31.2% |
| Return on Invested Capital (ROIC %) | -45.0% | -28.8% | — |
| Cash & Short-Term Equivalents | $65.3M | $71.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $196.1M | $299.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VYGR.